Skip to main content

Metzger Michael A's Form 4 filing

Syndax Pharmaceuticals Inc (SNDX) · filed Sep 22, 2021

Accession no.
0001562180-21-006060
Filed
Sep 22, 2021
Trade date
Sep 20-22, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $703.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Metzger Michael ACIK 0001507220Director, Officer (President and COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 20, 2021Common StockMOption exerciseAcquired+31,455$7.20+$226,47649,114Direct
Sep 20, 2021Common StockSSaleDisposed−31,455$19.24F2−$605,194.217,659Direct
Sep 21, 2021Common StockMOption exerciseAcquired+4,808$7.20+$34,617.622,467Direct
Sep 21, 2021Common StockSSaleDisposed−4,808$19.16F3−$92,121.2817,659Direct
Sep 22, 2021Common StockMOption exerciseAcquired+300$7.20+$2,16017,959Direct
Sep 22, 2021Common StockSSaleDisposed−300$19.02F4−$5,70617,659Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 20, 2021Common StockMOption exerciseDisposed−31,455$0.00$00Direct
Sep 21, 2021Common StockMOption exerciseDisposed−4,808$0.00$00Direct
Sep 22, 2021Common StockMOption exerciseDisposed−300$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The sale price ranged from $19.00 to $19.92

Referenced by the price of 1 transaction in Table I.

F3

The sale prices ranged from $19.02 to $19.31

Referenced by the price of 1 transaction in Table I.

F4

The sale prices ranged from $19.00 to $19.06

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)